Merus leaves Nasdaq after Genmab deal: what it means for Merus stock

Merus N.V. (NL0011606264) left Nasdaq after Genmab completed its acquisition, with the final cash consideration set at USD 97.00 per share. According to EdgeChat, the back-end merger became effective on December 29, 2025, and Nasdaq delisting followed on December 30, 2025.

Genmab deal defines the outcome

The transaction converted Merus from a publicly traded clinical-stage biotechnology company into a wholly owned Genmab entity. EdgeChat reports that the tender offer closed on December 12, 2025, after Genmab acquired 94.20 percent of the shares and paid USD 6.90 billion in tender consideration.

The announced transaction value was USD 8.00 billion, based on the USD 97.00 cash price applied across the outstanding shares. The consideration represented a 41.00 percent premium to Merus' USD 68.89 closing price on September 26, 2025, according to EdgeChat.

What the delisting means

For Merus stock, the central change is structural rather than operational: shareholders moved from an exchange-listed security to a cash entitlement under the completed merger. The former Nasdaq listing began in 2016, while the company was founded in 2003 and headquartered in Utrecht, according to EdgeChat.

Merus developed full-length human bispecific and trispecific antibodies through its Biclonics and Multiclonics platforms. Its lead candidate petosemtamab was in Phase 3 trials for head and neck cancer, while BIZENGRI, also known as zenocutuzumab-zbco, had received U.S. approval for cancers carrying an NRG1 gene fusion, the profile states.

Delisting fixes the market status

Merus shares were delisted from Nasdaq on December 30, 2025, after the merger converted the remaining minority shares into the right to receive USD 97.00 per share. Merus' investor-relations page lists the Genmab completion announcement among the company's latest news at Merus.

More news and analyses on Merus stock